The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles

References

• Fluker M, Grifo J, Leader A, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RZ Jr, Schoolcraft W, Shapiro DB. North American Ganirelix Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38–45.
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Bili HN. Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications. Curr Opin Obstet Gynecol 2003;15:259–264.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotropin- releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007;14:640–649.
   PubMed Web of Science ®Google Scholar
• Pinto F, Oliveira C, Cardoso MF, Silva JT, Silva J, Sousa M, Barros A. Impact of GnRH ovarian stimulation protocols on intracytoplasmic sperm injection outcomes. Reprod Biol Endocrinol 2009;15:5.
   Google Scholar
• Devaux A, Pouly JL, Bachelot A, Mourouvin Z, de Mouzon J. Biological effects of GnRH antagonists. Gynecol Obstet Fertil 2004;32:741–747.
   PubMedGoogle Scholar
• Ms K, Am M, Km MKG. Gonadotropin- releasing hormone antagonists in IVF/ICSI. J Hum Reprod Sci 2008;1:29–32.
   PubMedGoogle Scholar
• Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A, Martinez OJ. A randomized study of GnRH antagonist (Cetrorelix) versus agonist (Busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 2005;120:185–189.
   PubMed Web of Science ®Google Scholar
• Rashid MR, Ong FB, Omar MH, Ng SP, Nurshaireen A, Sharifah-Teh NS, Fazilah AH, Zamzarina MA. GnRH agonist and antagonist in ICSI cycles. Med J Malaysia 2008;63:113–117.
   PubMedGoogle Scholar
• Levi AJ, Drews MR, Bergh PA, Miller BT, Scott RT Jr. Controlled ovarian hyperstimulation does not adversely affect endometrial receptivity in in vitro fertilization cycles. Fertil Steril 2001;76:670–674.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Meltzer S, Rabinson J, Zohav E, Anteby EY, Nahum R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. Fertil Steril 2008;90:1294–1296.
   PubMed Web of Science ®Google Scholar
• Giannaris D, Zourla A, Chrelias C, Loghis C, Kassanos D. Ultrasound assessment of endometrial thickness: correlation with ovarian stimulation and pregnancy rates in IVF cycles. Clin Exp Obstet Gynecol 2008;35:190–193.
   PubMed Web of Science ®Google Scholar
• McWilliams GD, Frattarelli JL. Changes in measured endometrial thickness predict in vitro fertilization success. Fertil Steril 2007;88:74–81.
   PubMed Web of Science ®Google Scholar
• Richter KS, Bugge KR, Bromer JG, Levy MJ. Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos. Fertil Steril 2007;87:53–59.
   PubMed Web of Science ®Google Scholar
• Rashidi BH, Sadeghi M, Jafarabadi M, Tehrani Nejad ES. Relationship between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern. Eur J Obstet Gynecol Reprod Biol 2005;120:179–184.
   PubMed Web of Science ®Google Scholar
• Bassil S. Changes in endometrial thickness, width, length and pattern in predicting pregnancy outcome during ovarian stimulation in in vitro fertilization. Ultrasound Obstet Gynecol 2001;18:258–263.
   PubMed Web of Science ®Google Scholar
• Baczkowski T, Kurzawa R, Glabowski W. Methods of embryo scoring in in vitro fertilization. Reprod Biol 2004;4:5–22. Review.
   PubMedGoogle Scholar
• Detti L, Yelian FD, Kruger ML, Diamond MP, Puscheck EE. Endometrial thickness dynamics and morphologic characteristics during pituitary down regulation with antagonists in assisted reproductive technology cycles. J Ultrasound Med 2008;27:1591–1596.
   PubMed Web of Science ®Google Scholar
• Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000;15:1211–1216.
   PubMed Web of Science ®Google Scholar
• Detti L, Yelian FD, Kruger ML, Diamond MP, Rode A, Mitwally MF, Puscheck EE. Endometrial thickness is related to miscarriage rate, but not to the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist. Fertil Steril 2008;89:998–1001.
   PubMed Web of Science ®Google Scholar
• Prapas N, Tavaniotou A, Panagiotidis Y, Prapa S, Kasapi E, Goudakou M, Papatheodorou A, Prapas Y. GnRH antagonists and endometrial receptivity in oocyte recipients: a randomized prospective trial. Reprod Biomed Online 2009;18:276–281.
   PubMed Web of Science ®Google Scholar
• Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B, et al. Similar endometrial development in oocyte donors treated with either high- or standard- dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 2005;20:3318–3327.
   PubMed Web of Science ®Google Scholar
• Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril 2008;89:1234–1239.
   PubMed Web of Science ®Google Scholar
• Souza Mdo C, Souza MM, Oliveira JB, Henriques CA, Cardoso FF, Mancebo AC, Rocha CA. Use of antral follicle count to predict the response pattern in controlled ovarian hyperstimulation cycles with GnRH antagonist. Rev Bras Ginecol Obstet 2008;30:36–41.
   PubMedGoogle Scholar
• Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PMM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008;23:310–315.
   PubMed Web of Science ®Google Scholar